Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch).
The Company is in Phase 3 clinical development for uremic pruritus and prurigo nodularis.
Trevi Therapeutics Announces Completion of Enrollment in Phase 2/3 Study of Nalbuphine ER in Prurigo Nodularis
6/2/2016
Company expects to report data in Q3 2016
Trevi Therapeutics to Present Two Posters at the National Kidney Foundation Spring 2016 Meeting
4/28/2016
Authors available to discuss clinical studies results regarding Nalbuphine ER for hemodialysis patients with uremic pruritus
Trevi Therapeutics' Data to be Presented at the American Academy of Dermatology's 74th Annual Meeting in Washington, DC
3/1/2016
Presentation Abstract: Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients with Uremic Pruritus